Business Monitor International


Qatar Pharmaceuticals & Healthcare Report

Published 24 December 2014

  • 101 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Qatar Pharmaceuticals & Healthcare Report

BMI View: With Qatar's Supreme Council of Health announcing the completion of its master plan for healthcare facilities in Qatar covering the period 2013-2033, the country is poised to invest in healthcare infrastructure. Meanwhile, the Qatari government has decided to make health insurance compulsory for non-nationals. The new law will ensure more competitive pricing of services among healthcare providers in the country, as it will enable residents to choose between private and public hospitals. Moreover, it will reduce government spending for maintaining its healthcare system on non-nationals. Economic and political stability, in addition to projected growth in the pharmaceutical and healthcare markets, will ensure that Qatar remains a small but attractive market.

Headline Expenditure Projections

  • Pharmaceuticals: QAR1.67bn (USD459mn) in 2013 to QAR1.88bn (USD516mn) in 2014; +12.6% in local currency and 12.5% in US dollar terms. Forecast upwardly revised from Q414.

  • Healthcare: QAR16.49bn (USD4.53bn) in 2013 to QAR18.20bn (USD5.00bn) in 2014; +10.4% in both local currency and US dollar terms. Forecast revised downwards due to macroeconomic modifications.

Risk/Reward Index

Qatar's risks are particularly low in comparison with the rest of the MEA region, although its potential rewards are dampened by the small market size. Nevertheless, Qatar's high level of urbanisation, rapid population growth and rising prevalence of chronic lifestyle diseases creates an environment in which there is strong potential for market growth. On account of shifts within BMI's Pharmaceutical Risk/Reward Index for the Middle East and Africa matrix in Q115, Qatar has moved again, up one position in the MEA matrix to sixth place, with the country's score this quarter increasing to 55.5 out of 100.

Key Trends And Developments

November 2014

  • The Qatari government made health insurance compulsory for non-nationals. With 94% of the current work force in Qatar consisting of foreign...

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Qatar 2010-2018)
20
Healthcare Market Forecast
21
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2010-2018)
23
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2010-2018)
23
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2010-2018)
23
Prescription Drug Market Forecast
24
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
25
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
26
Generic Drug Market Forecast
27
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
30
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (Qatar 2012-2018)
32
Table: Pharmaceutical Trade Data And Forecasts local currency (Qatar 2012-2018)
32
Other Healthcare Data
33
Table: Healthcare Professionals (2009)
34
Key Risks To BMI's Forecast Scenario
35
Macroeconomic Forecasts
37
Industry Risk Reward Ratings
47
Middle East & Africa Risk/Reward Index
47
Qatar Risk/Reward Ratings
54
Rewards
54
Risks
55
Market Overview
56
Industry Trends And Developments
57
Epidemiology
57
Healthcare Sector
62
Healthcare Sector Developments
63
Health Insurance
66
Healthcare IT
67
Research & Development
68
Clinical Trials
70
Regulatory Development
71
Regional Regulatory Developments
72
Intellectual Property Regime
75
Pricing And Reimbursement Regime
75
Competitive Landscape
78
Pharmaceutical Industry
78
Pharmaceutical Wholesale And Retail
79
Company Profile
81
Medicare Group
81
Ebn Sina Medical
83
Qatar Pharma
85
Novartis
87
Merck & Co
89
GlaxoSmithKline
91
Pfizer
93
Demographic Forecast
95
Table: Qatar's Population By Age Group, 1990-2020 ('000)
96
Table: Qatar's Population By Age Group, 1990-2020 (% of total)
97
Table: Qatar's Key Population Ratios, 1990-2020
98
Table: Qatar's Rural And Urban Population, 1990-2020
98
Glossary
99
Methodology
101
Pharmaceutical Expenditure Forecast Model
101
Healthcare Expenditure Forecast Model
101
Notes On Methodology
102
Risk/Reward Ratings Methodology
103
Ratings Overview
104
Table: Pharmaceutical Risk/Reward Ratings Indicators
104
Indicator Weightings
105

The Qatar Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Qatar Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Qatar pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Qatar, to test other views - a key input for successful budgeting and strategic business planning in the Qatari pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Qatari pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Qatar.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc